Lasting Controversy on Ranibizumab and Bevacizumab
作者: Lihui ZouHuiying LaiQi ZhouFei Xiao
刊名: Theranostics, 2011, Vol.1 , pp.395-402
来源数据库: Ivyspring Journal
原始语种摘要: Vascular endothelial growth factor (VEGF), an important angiogenic factor that is able to stimulate the proliferation and migration of endothelial cells, is the best-studied hallmark of angiogenesis. Neovascularization is a major cause of age-related macular degeneration (AMD) which is a leading cause of blindness in the elderly population. Specific molecular inhibitors of VEGF have been proved to be useful in the treatment of AMD. Ranibizumab and Bevacizumab are structurally similar to anti-VEGF drugs in the treatment of AMD. Many studies have indicated that Ranibizumab and Bevacizumab are of roughly equal short-term efficacy and safety, Bevacizumab is an attractive alternative to Ranibizumab due to its lower cost. However, only Ranibizumab has received Food and Drug Administration (FDA)...
全文获取路径: Ivyspring 

  • treatment 处理
  • studied 学习
  • achieved 获得的
  • safety 安全
  • factor 因素
  • macular 具斑点的
  • drugs 药品
  • cause 引起
  • attractive 有吸引力的
  • structurally 在结构上